We see option activity picking up in our favorite Latin American payment service company. Morgan Stanley analysts expect stronger than expected growth. The chart looks interesting for the stock to run again.
Valuations are compelling in Emerging Markets, but momentum is weak. Seasonally, June is weak. Gold and silver show strength against dollar weakness.
Tesla, the best innovator with first mover advantage in EV space, gets all the attention. It has a lofty multiple while other auto makers were shunned. Recently, new products signal a change.
JPMorgan makes the case for an early stage growth opportunity within an established company: Urban Air Travel.
Animal Health companies are showing strength recently. Four stocks are poised for new highs as demand for products remain elevated, according to Credit Suisse.
A buying opportunity in a medtech company arises as a competitor product pulls out.
Divergent markets pervade June. The NASDAQ ends its best 8 months and the Dow can really suffer, especially in post-election years.
The debate on the sustainability of inflation is alive! Markets react and traders battle out their Feds next move. Retail and consumer discretionary stocks look weak, while semiconductors and car resellers could bounce. Biotech sits on support.
A long standing bear case has eroded sentiment in this once loved oil stock. After latest earnings, the CEO says the environment is changing. A re-rating in the stock is likely.
SPX gets extremely overbought. Our Core Strategy catches up. A breakout in RUTH is possible.
